Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Multiple Sclerosis: early-phase trial registry
120 of 317 indexed Multiple Sclerosis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #24 of 28,707 conditions by registered trial count.
317 US clinical trials · 120 currently recruiting · #24 of 28,707 conditions by registered trial count
Multiple Sclerosis: 317 US clinical trials tracked, 120 recruiting.
Multiple Sclerosis is the subject of 317 registered US clinical trials on ClinicalTrials.gov, 120 of them currently open to new participants. 41 are in Phase 3-4 (later-stage) and 74 in Phase 1-2 (earlier-stage). The most active sponsor is Biogen, running 13 of these trials.
Enrollment posture brief
Registry condition multiple-sclerosis
OPEN 120 | RECR 38% | LATE 41 | EARLY 74 | RANK #24 | SPON 13
Volume-matched condition peers
Nearest open-share peer: Multiple Myeloma (38% recruiting · 441 trials)
Multiple Sclerosis lists 120 open slots (38% of 317 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Multiple Sclerosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Multiple Sclerosis recruits in line with its size-band peers.
120 of 317 indexed trials (37.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Multiple Sclerosis trials is spread across many organizations.
Biogen accounts for 13 of 317 trials (4.1%). 142 distinct sponsors appear on at least one study for this condition label.
-
Typical Multiple Sclerosis enrolment sits around 61 participants.
Median target enrolment is 61 among the 316 trials that report a genuine target (sentinel values excluded). 181 of those (57.3%) plan for fewer than 100 participants.
-
Multiple Sclerosis research is mostly interventional.
231 interventional and 86 observational studies make up this index (72.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
317 total, page 3 of 7
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
AstraZeneca
NCT07224373
Meeting an Unmet Need in Multiple Sclerosis
Kessler Foundation
NCT05953519
Exercise Rehabilitation Program in MS Who Use Wheelchairs as a Primary Mobility Device
University of Illinois at Chicago
NCT06410261
Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS
Shirley Ryan AbilityLab
NCT06390930
Intermittent Hypoxia in Persons With Multiple Sclerosis
Shirley Ryan AbilityLab
NCT06276634
Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis
Novartis Pharmaceuticals
NCT06444113
Entire-body PET Scans for Multiple Sclerosis
Brain Health Alliance
NCT04390009
Effects of High-intensity Gait Training on Fatigue, Gait, and Neuroplasticity in People With Multiple Sclerosis
University of Illinois at Chicago
NCT06264336
Molecular Imaging of NET Using [C-11]MRB-PET in MS
Brigham and Women's Hospital
NCT03207464
Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy
National Institute of Neurological Disorders and Stroke (NINDS)
NCT05849467
Task Specific Training for Advanced Multiple Sclerosis
Hunter College of City University of New York
NCT06506929
Evaluation of the Safety and Efficacy of a Full-Body Electrostimulation Garment for Individuals With Neurological and Neuromuscular Conditions That Cause Spasticity, Hyperreflexia, and Pain
Shirley Ryan AbilityLab
NCT07132775
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
Cionic
NCT05964829
Deciphering Preserved Autonomic Function After Multiple Sclerosis
Mayo Clinic
NCT07012135
Vancomycin Study in Multiple Sclerosis (MS)
Icahn School of Medicine at Mount Sinai
NCT05539729
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
Stanford University
NCT06138132
Acceptability and Feasibility of Transcranial Magnetic Stimulation (TMS) for Depression in Multiple Sclerosis
University of Utah
NCT06329414
Investigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MS
Kessler Foundation
NCT04855825
Non-invasive Electrical Spinal Cord Stimulation To Restore Upper Extremity Function in Multiple Sclerosis
University of Washington
NCT06552611
ECoG BMI for Motor and Speech Control
Karunesh Ganguly
NCT03698149
A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)
Biogen
NCT05767736
Biobank For MS And Other Demyelinating Diseases
Accelerated Cure Project for Multiple Sclerosis
NCT00445367
A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their Infants
Bristol-Myers Squibb
NCT06133049
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
Hoffmann-La Roche
NCT05269004
Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
Immunic
NCT05134441
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
Hoffmann-La Roche
NCT04544436
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
Hoffmann-La Roche
NCT04548999
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
Immunic
NCT05054140
Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis
The Cleveland Clinic
NCT04495556
A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)
Biogen
NCT05925049
Evaluating the Immune Response to COVID19 Vaccination in Immunodeficient Patients
Yale University
NCT05286242
MS-DETECT: Early Detection of Multiple Sclerosis Progression With MSCopilot® Detect
Ad scientiam
NCT05816122
Stratification of Risks of Conversion of Radiologically Isolated Syndromes (RIS) by Identifying Biomarkers in Serum and Cerebrospinal Fluid.
Centre Hospitalier Universitaire de Nīmes
NCT06395662
Optimizing Detection and Prediction of Changes in Cognitive Function in Multiple Sclerosis (MS)
University of Michigan
NCT05252195
Project BIPAMS: Behavioral Intervention for Physical Activity in Multiple Sclerosis
University of Alabama at Birmingham
NCT03490240
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
Novartis Pharmaceuticals
NCT01892722
The Use of Technology to Improve MS Clinical Trials and Patient Care
Johns Hopkins University
NCT02454907
Portable Neuromodulation Stimulator Registry for People With Multiple Sclerosis
Helius Medical
NCT06930339
Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis
Sanofi
NCT04879628
VIRtual Versus UsuAL In-office Care for Multiple Sclerosis (VIRTUAL-MS)
The Cleveland Clinic
NCT05660187
KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis
Kyverna Therapeutics
NCT06384976
Evaluation of a Theory-Driven Manualized Approach to Improving New Learning and Memory in MS
Kessler Foundation
NCT03983681
Multiple Sclerosis Falls Insight Track
University of California, San Francisco
NCT05837949
A Closed Loop, Doctor to Patient, Mobile Application for Depression in People With Multiple Sclerosis
University of California, San Francisco
NCT05865405
Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis
Emmanuelle Waubant, MD PhD
NCT05122559
A Novel Wearable Digital Biomarker for Detecting Changes in Multiple Sclerosis (MS) Condition
Celestra Health Systems
NCT05781113
TRAIN-BW: Backward Walking Training in Multiple Sclerosis
Wayne State University
NCT04091464
MSCopilot Users' Feedback in Real Life - Outcomes Regarding Integration in Patients' pathWay and Users' ExpeRience
Ad scientiam
NCT06922942
Home Based Tele-exercise for People With Chronic Neurological Impairments
Burke Medical Research Institute
NCT04564495
A Health Action Process Approach Online Intervention for People With Multiple Sclerosis
University of Illinois at Urbana-Champaign
NCT05124522
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 41 |
| Phase 2 | 33 |
| Phase 3 | 24 |
| Phase 4 | 17 |
Top Sponsors
Named interventions
Most-linked intervention names on Multiple Sclerosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Multiple Sclerosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Multiple Sclerosis page
317 registered trials, 120 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 120 Multiple Sclerosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Biogen sponsors the most Multiple Sclerosis trials on record, review their full trial history before evaluating a specific study. See Biogen's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Multiple Sclerosis condition card totals 317 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.